Gary Meininger

16.0k total citations · 8 hit papers
80 papers, 8.3k citations indexed

About

Gary Meininger is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Molecular Biology. According to data from OpenAlex, Gary Meininger has authored 80 papers receiving a total of 8.3k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Endocrinology, Diabetes and Metabolism, 52 papers in Surgery and 10 papers in Molecular Biology. Recurrent topics in Gary Meininger's work include Diabetes Treatment and Management (68 papers), Pancreatic function and diabetes (45 papers) and Diabetes Management and Research (35 papers). Gary Meininger is often cited by papers focused on Diabetes Treatment and Management (68 papers), Pancreatic function and diabetes (45 papers) and Diabetes Management and Research (35 papers). Gary Meininger collaborates with scholars based in United States, Canada and United Kingdom. Gary Meininger's co-authors include William Canovatchel, Keith Usiskin, Mehul Desai, William T. Cefalu, Dainius Balis, Ujjwala Vijapurkar, Kaj Stenlöf, Maria Alba, C. Tong and Vlado Perkovic and has published in prestigious journals such as The Lancet, Journal of the American College of Cardiology and American Journal of Clinical Nutrition.

In The Last Decade

Gary Meininger

79 papers receiving 8.0k citations

Hit Papers

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibit... 2006 2026 2012 2019 2006 2013 2007 2012 2013 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone
    2006 637 citations Gary Meininger et al. Diabetes Care profile →
  2. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
    2013 606 citations Lawrence A. Leiter, Kun‐Ho Yoon et al. profile →
  3. Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial
    2007 529 citations Gary Meininger et al. Diabetes Obesity and Metabolism profile →
  4. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
    2012 513 citations Kaj Stenlöf, Maria Alba et al. Diabetes Obesity and Metabolism profile →
  5. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
    2013 418 citations J.‐F. Yale, George L. Bakris et al. Diabetes Obesity and Metabolism profile →
  6. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial
    2013 406 citations Fernando J. Lavalle‐González, Andrzej Januszewicz et al. Diabetologia profile →
  7. Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea
    2013 404 citations Jacqueline Yee, William Canovatchel et al. Diabetes Care profile →
  8. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
    2015 337 citations Keith Usiskin, Mehul Desai et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gary Meininger United States 40 7.3k 3.8k 3.0k 1.4k 639 80 8.3k
James F. List United States 32 6.7k 0.9× 3.3k 0.9× 3.5k 1.2× 1.3k 0.9× 666 1.0× 46 7.3k
Shamik Parikh United States 33 4.6k 0.6× 2.2k 0.6× 2.6k 0.9× 987 0.7× 424 0.7× 60 5.9k
Avivit Cahn Israel 29 7.7k 1.0× 3.0k 0.8× 3.1k 1.0× 839 0.6× 824 1.3× 113 9.3k
Jaime A. Davidson United States 35 6.6k 0.9× 2.7k 0.7× 2.4k 0.8× 745 0.5× 218 0.3× 98 8.2k
Boaz Hirshberg United States 41 6.2k 0.8× 3.5k 0.9× 2.7k 0.9× 990 0.7× 219 0.3× 118 8.7k
Greg Fulcher Australia 32 7.8k 1.1× 3.4k 0.9× 2.9k 1.0× 873 0.6× 1.1k 1.7× 65 9.5k
Steven P. Marso United States 31 9.0k 1.2× 3.2k 0.8× 3.4k 1.1× 1.9k 1.3× 451 0.7× 74 11.2k
Hans J. Woerle Germany 49 11.4k 1.6× 5.5k 1.5× 5.1k 1.7× 1.6k 1.1× 1.8k 2.8× 89 13.3k
Eri Kato Japan 15 6.0k 0.8× 2.5k 0.7× 2.5k 0.8× 670 0.5× 657 1.0× 47 7.5k
Thomas A. Zelniker United States 21 6.8k 0.9× 2.8k 0.7× 2.8k 0.9× 748 0.5× 744 1.2× 68 8.8k

Countries citing papers authored by Gary Meininger

Since Specialization
Citations

This map shows the geographic impact of Gary Meininger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Meininger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Meininger more than expected).

Fields of papers citing papers by Gary Meininger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary Meininger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Meininger. The network helps show where Gary Meininger may publish in the future.

Co-authorship network of co-authors of Gary Meininger

This figure shows the co-authorship network connecting the top 25 collaborators of Gary Meininger. A scholar is included among the top collaborators of Gary Meininger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary Meininger. Gary Meininger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yuan, Žhong, Frank DeFalco, Laura Hester, et al.. (2020). Acute pancreatitis risk in type 2 diabetes patients treated with canagliflozin versus other antihyperglycemic agents: an observational claims database study. Current Medical Research and Opinion. 36(7). 1117–1124. 3 indexed citations
2.
Nunez, Derek J., M Alexander, Laura M. Yerges‐Armstrong, et al.. (2018). Factors influencing longitudinal changes of circulating liver enzyme concentrations in subjects randomized to placebo in four clinical trials. American Journal of Physiology-Gastrointestinal and Liver Physiology. 316(3). G372–G386. 5 indexed citations
3.
Heerspink, Hiddo J.L., Mehul Desai, Meg Jardine, et al.. (2016). Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects. Journal of the American Society of Nephrology. 28(1). 368–375. 263 indexed citations
4.
Qiu, Rong, Dainius Balis, John Xie, et al.. (2016). Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis. Current Medical Research and Opinion. 33(3). 553–562. 27 indexed citations
5.
Gilbert, Richard E., Matthew R. Weir, Paola Fioretto, et al.. (2016). Impact of Age and Estimated Glomerular Filtration Rate on the Glycemic Efficacy and Safety of Canagliflozin: A Pooled Analysis of Clinical Studies. Canadian Journal of Diabetes. 40(3). 247–257. 12 indexed citations
6.
Davidson, Jaime A., et al.. (2016). Efficacy and Safety of Canagliflozin in Patients With Type 2 Diabetes Mellitus of Different Ethnicity. Ethnicity & Disease. 26(2). 221–221. 9 indexed citations
7.
Blonde, Lawrence, Kaj Stenlöf, Albert Fung, et al.. (2016). Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgraduate Medicine. 128(4). 371–380. 55 indexed citations
8.
Gavin, James R., Melanie J. Davies, Michael J. Davies, et al.. (2015). The efficacy and safety of canagliflozin across racial groups in patients with type 2 diabetes mellitus. Current Medical Research and Opinion. 31(9). 1693–1702. 16 indexed citations
9.
Wyne, Kathleen, et al.. (2015). EFFECT OF CANAGLIFLOZIN ON TRIGLYCERIDE-TO-HIGH DENSITY LIPOPROTEIN CHOLESTEROL RATIO, A MARKER OF INSULIN RESISTANCE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. Journal of the American College of Cardiology. 65(10). A2127–A2127. 1 indexed citations
10.
Perkovic, Vlado, Meg Jardine, Ujjwala Vijapurkar, & Gary Meininger. (2015). Renal effects of canagliflozin in type 2 diabetes mellitus. Current Medical Research and Opinion. 31(12). 2219–2231. 47 indexed citations
11.
Bailey, Robert A., Ujjwala Vijapurkar, Gary Meininger, Marcia F.T. Rupnow, & Lawrence Blonde. (2014). Diabetes-related quality measure attainment: canagliflozin versus sitagliptin based on a pooled analysis of 2 clinical trials.. PubMed. 20(13 Suppl). s296–305. 16 indexed citations
12.
13.
Yamout, Hala, Vlado Perkovic, Melanie J. Davies, et al.. (2014). Efficacy and Safety of Canagliflozin in Patients with Type 2 Diabetes and Stage 3 Nephropathy. American Journal of Nephrology. 40(1). 64–74. 91 indexed citations
14.
Weir, Matthew R., Andrzej Januszewicz, Richard E. Gilbert, et al.. (2014). Effect of Canagliflozin on Blood Pressure and Adverse Events Related to Osmotic Diuresis and Reduced Intravascular Volume in Patients With Type 2 Diabetes Mellitus. Journal of Clinical Hypertension. 16(12). 875–882. 101 indexed citations
15.
Meininger, Gary, et al.. (2013). Canagliflozin added on to dipeptidyl peptidase-4 inhibitors or glucagon-like peptide-1 agonists with or without other antihyperglycaemic agents in type 2 diabetes mellitus. Diabetologia. 56.
16.
Lavalle‐González, Fernando J., Andrzej Januszewicz, Jaime A. Davidson, et al.. (2013). Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 56(12). 2582–2592. 406 indexed citations breakdown →
17.
Yale, J.‐F., George L. Bakris, Bertrand Cariou, et al.. (2013). Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obesity and Metabolism. 15(5). 463–473. 418 indexed citations breakdown →
18.
Wilding, John, G. Charpentier, Priscilla Hollander, et al.. (2013). Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. International Journal of Clinical Practice. 67(12). 1267–1282. 276 indexed citations
19.
Meininger, Gary, Sara Dolan, Colleen Hadigan, et al.. (2004). Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients. AIDS. 18(3). 465–473. 103 indexed citations
20.
Meininger, Gary & D. Harder. (2001). Lochkamera-Untersuchungen zum Streustrahlungsanteil und zur Größe der Photonenquelle eines Linearbeschleunigers. Zeitschrift für Medizinische Physik. 11(1). 53–56. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by James F. List Breakdown of academic impact, for papers by Shamik Parikh Breakdown of academic impact, for papers by Avivit Cahn Breakdown of academic impact, for papers by Jaime A. Davidson Breakdown of academic impact, for papers by Boaz Hirshberg Breakdown of academic impact, for papers by Greg Fulcher Breakdown of academic impact, for papers by Steven P. Marso Breakdown of academic impact, for papers by Hans J. Woerle Breakdown of academic impact, for papers by Eri Kato Breakdown of academic impact, for papers by Thomas A. Zelniker
Rankless by CCL
2026